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Abstract
Background: Understanding the factors affecting the mode and timeliness of breast cancer diagnosis is
important to optimizing patient experiences and outcomes. The purposes of the study were to identify
factors related to the length of the diagnostic interval and assess how they vary by mode of diagnosis:
screen or symptom detection.
Methods: All female residents of Alberta diagnosed with first primary breast cancer in years 2004–2010
were identified from the Alberta Cancer Registry. Data were linked to Physician Claims and screening
program databases. Screen-detected patients were identified as having a screening mammogram within
6-months prior to diagnosis; remaining patients were considered symptom-detected. Separate quantile
regression was conducted for each detection mode to assess the relationship between demographic/clinical
and healthcare factors.
Results: Overall, 38 % of the 12,373 breast cancer cases were screen-detected compared to 47 % of the
screen-eligible population. Health region of residence was strongly associated with cancer detection mode.
The median diagnostic interval for screen and symptom-detected cancers was 19 and 21 days, respectively.
The variation by health region, however, was large ranging from an estimated median of 4 to 37 days for
screen-detected patients and from 17 to 33 days for symptom-detected patients. Cancer stage was inversely
associated with the diagnostic interval for symptom-detected cancers, but not for screen-detected cancers.
Conclusion: Significant variation by health region in both the percentage of women with screen-detected
cancer and the length of the diagnostic interval for screen and symptom-detected breast cancers suggests
there could be important differences in local breast cancer diagnostic care coordination.
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Background
Breast cancer is the most commonly diagnosed cancer
among Canadian women and the second most common
cause of their cancer death [1]. Prognosis is best when
diagnosed and treated at an early stage; timely diagnosis
and early detection are, therefore, critical to optimizing
survival. In Canada, early detection is facilitated by guide-
line recommendation of routine screening for breast can-
cer with mammography for average risk women aged 50
to 69 every 2 years; also, the Canadian Association of Ra-
diologists recommends that women between 40 and 49
also be screened annually [2, 3]. Similar recommendations
and breast cancer screening programs exist in most devel-
oped countries, as screening has been shown to reduce
mortality by 20 to 30 % [4–6].
Regardless of the mode of detection, timely diagnostic
resolution following detection of breast abnormalities is
important. Delayed resolution is associated with larger
tumors, locally advanced or metastatic cancer, higher re-
currence rates, lower 5-year survival rates, and increased
patient anxiety [7–9]. Diagnostic delays of three months
or more in symptom-detected breast cancer are associ-
ated with a 12 % lower 5-year survival compared to
those with shorter delays [10]. Delayed resolution of
false positive screening mammograms has also been as-
sociated with decreased participation in subsequent
screening [11]. Given the public health impact of breast
cancer and the value of early detection and timely diag-
nosis, it is important to understand factors related to
timely breast cancer diagnosis and the relationship be-
tween mode of diagnosis and diagnostic interval to
optimize the patient care experience and, ultimately, sur-
vival of breast cancer patients.
Here we investigate mode of detection and time to
breast cancer diagnosis in Alberta, Canada and report
findings on 1) the proportion of screen vs. symptom-
detected breast cancers, 2) time to diagnosis by mode of
detection and 3) identify patient demographic, clinical
and healthcare system factors related to mode of detec-
tion and time to diagnosis.
Methods
Study population
A retrospective breast cancer cohort of female residents
of Alberta, who were diagnosed with a histologically
confirmed first-ever primary breast cancer (International
Classification of Disease for Oncology (ICD-O) 3rd edi-
tion code C50 behaviors 2 and 3 [12]) in years 2004 to
2010, was identified from the Alberta Cancer Registry, a
population based cancer registry recognized for data
completeness by the North American Association of
Central Cancer Registries. All patients were included un-
less data to calculate outcome measures, as defined
below, were missing.
During the study period, the province of Alberta had a
population of about 3 to 3.5 million spread over
662,000 km2 [13]. Approximately 56 % of the total popu-
lation live within the two urban regions, 27 % live in
small and medium regional cities, and roughly 17 % live
in rural and remote areas [14]. Alberta has a publicly-
funded provincially operated single-payer health care
system, in which all residents have free access to stand-
ard medical care. The majority of physicians are remu-
nerated via fee-for-service. Typically women are referred
for mammography by their primary care physician (PCP)
but screen-eligible patients can self-refer.
Data sources and variables
The following patient characteristics were obtained from
the Alberta Cancer Registry: age, postal code of resi-
dence, regional health authority (RHA) of residence,
disease stage, histologic grade and date of diagnosis. Dis-
ease stage was based on the American Joint Committee
on Cancer staging [15]. Histology grade was based on
the ICD-O morphology grade that represents the degree
of differentiation of the tumor.
The postal codes of patients were used to obtain
neighbourhood-level variables developed by Statistics
Canada. Specifically, neighbourhood income level (in
quintiles, QAIPPE) and an urban/rural variable (CSIZE-
MIZ) were obtained by linking patient postal codes to
the 2006 Canadian Census Data [16]. The latter variable
is defined by categorizing communities with populations
less than 10,000 that have no influence from larger cities
as rural and all other communities as urban.
International Classification of Disease, Tenth Revision,
Clinical Modification [ICD-10-CM] diagnosis codes from
three provincial administrative health care databases were
used to calculate the Charlson Comorbidity Index: 1) the
Ambulatory Care Classification System, all outpatient
visits to hospitals in the province; 2) the Discharge
Abstract Database, all inpatient hospital admissions in the
province, and 3) the Physician Claims Database, all fee-
for-service physician visits. All relevant codes in the period
30 months prior to breast cancer diagnosis were used to
calculate the modified Charlson Comorbidity Index, [17,
18]. Codes for primary or metastatic cancer were excluded
from calculations.
The Physician Claims Database was used to identify
visits to a PCP using the ‘provider type’ code to calculate
the Usual Provider Continuity (UPC) score. The UPC is
calculated by dividing the number of visits to the PCP
the patient has seen the most by the total number of all
PCP visits a patient has had in a given time period [19,
20]. In order to capture typical PCP utilization, all PCP
visits from 6 to 30 months prior to cancer diagnosis
were included in the UPC calculation and a minimum of
three PCP visits was required to calculate the UPC.
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Patients with less than three PCP visits in the period
were classified as having “minimum PCP visits”.
The databases and datasets used in the study are not
publicly available. The Alberta Cancer Registry data were
made available upon ethics approval. The provincial ad-
ministrative databases are governed by Alberta Health
Services (AHS) via permission from the provincial min-
istry, Alberta Health (AH). AHS provided the provincial
administrative data required for the study after reviewing
the study protocol, receiving a signed confidentiality
agreement (from MW) and receiving proof of ethics ap-
proval. Ethics approval for the study was obtained from
the University of Alberta Health Research Ethics Board.
Outcome measures
The outcome measures are percent screen-detected
cancers and the length of the diagnostic interval. All
breast cancer related diagnostic procedures, including
screening/diagnostic mammograms, breast ultrasound
and breast biopsies, were identified from the Physician
Claims Database and the Screen Test Database. These
two databases are complementary, capturing all breast
cancer related screening and diagnostic procedures in
the province from fee-for service and salaried radiolo-
gists, respectively. All breast-related procedures within a
validated look-back period [21] from the date of diagno-
sis in the Alberta Cancer Registry were obtained.
Breast cancer was defined as screen-detected if the pa-
tient had a screening mammogram within the look-back
period. The length of the diagnostic interval was defined
as the time from the date of the screening mammogram
to the date of breast cancer diagnosis, typically the first
positive percutaneous or surgical biopsy date. The
remaining cancers were defined as symptom-detected.
The earliest breast cancer related diagnostic procedure in
the look-back period, usually a diagnostic mammogram,
was defined as the first relevant diagnostic test. The most
proximal visit to a PCP within 6-months prior to the first
relevant test was defined as the start of the diagnostic
interval for symptom-detected patients, because in most
cases a diagnostic test can only be conducted if a referral
is made by a PCP. The diagnostic interval for symptom-
detected patients, therefore, is defined as the time interval
from the date of the PCP visit to the date of cancer
diagnosis. Figure 1 summarizes the diagnostic interval
by detection method as described above.
Data were linked using the unique provincial health-
care identification number which was anonymized for
data analysis. Quality assurance and cross checks
were performed on data sets during and after data
linkage to ensure accuracy and completeness. Ethical
approval was obtained from the Human Research
Ethics Board at the University of Alberta before con-
ducting the study.
Statistical analyses
Demographic, clinical and healthcare system factors
were assessed for their univariate associations with each
of the outcome measures. Chi-square tests were calcu-
lated to assess associations with percent screen-detected
breast cancers and Kruskal-Wallis tests were calculated
to assess associations with the length of the diagnostic
interval. The demographic factors evaluated were age and
neighbourhood income quintile. Patients were grouped as
follows: 39 and under, 40–49, 50–69, 70–74, and 75 and
over. The age groupings were based on screening guide-
lines and clinical practice in Alberta: 50–69 is the screen-
eligible age group during the study period [22]; women
Fig. 1 An illustration of the diagnostic interval for screen and symptom detected breast cancers. For the screen-detected cancers (panel a), the
diagnostic interval is the time between the date of diagnosis and the date of the screening mammogram, a maximum of 6 months. For the
symptom-detected cancers (panel b), the diagnostic interval is the time between the date of diagnosis and the date of the most proximal GP visit
prior to the first diagnostic test, a maximum of 12 months
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aged 70–74 are included in the most recent breast screen-
ing guideline [23]; and women aged 40–49 years old can
be referred for breast cancer screening in practice. Clinical
factors included cancer stage at diagnosis, histology grade,
and Charlson comorbidity index. Healthcare system fac-
tors included time period of cancer diagnosis, Usual Pro-
vider Continuity score (UPC), regional health authority
(RHA), and urban/rural residence. The cut point for the
time period variable was chosen based on the observed
trend of percent screen-detected cancers over the years.
Time period 1 includes cancers diagnosed in years 2004 to
2006 and time period 2 includes cancers diagnosed in
years 2007 to 2010.
Multivariable logistic regression was used to exam-
ine the association of factors on the likelihood of can-
cer being screen-detected. The most parsimonious
model was identified and presented as the final
model. The interaction of time period by RHA was
hypothesized and tested; the interaction was statisti-
cally significant and kept in the final model. For the
diagnostic interval outcome, multivariable quantile re-
gression models were fitted to estimate the effects of
individual factors and the interaction effects between
RHA and time period for screen and symptom de-
tected patients separately. Briefly, quantile regression
is similar to linear regression; it differs by modeling
the median or specific quantiles defined by the user
rather than the mean. For non-symmetric distribu-
tions such as time intervals, quantile regression is
more appropriate than linear regression. The esti-
mates from quantile regression are the difference in
diagnostic interval (days) associated with each factor,
making it simple to understand. Quantile regression
models were run for the median and the 90th per-
centile; the 90th percentile was intended to represent
diagnostic delay. All analyses were conducted using
SAS 9.4 (SAS Institute, Cary NC).
Results
Mode of diagnosis
There were 12,813 first-ever female breast cancers di-
agnosed in Alberta residents in years 2004 to 2010;
440 (3.4 %) were excluded from the study because of
missing data that prevented the assignment of detec-
tion mode. Table 1 gives the descriptive statistics of
the demographic, clinical, and healthcare system fac-
tors of the breast cancer patient cohort by detection
mode. About 38 % of the cancer cases were screen-
detected overall. Roughly 50 % of patients were in the
screen-eligible age group (50 to 69 years of age), of
whom 47 % were screen-detected. In the whole cohort,
the majority of screen-detected patients, 72 %, had in situ
or stage I cancer compared to only 39 % in the symptom-
detected patients (P < 0.001). Similarly, screen-detected
cancers had a lower histological grade than the symptom-
detected cancers; 25 % of screen-detected tumors
were low grade compared to 16 % of symptom de-
tected (P < 0.001). About 57 % of screen-detected in
situ cancers, however, were high grade (nuclear) com-
pared to 50 % of those symptom-detected (P = 0.01, data
not shown). Similar contrasts by detection mode were
found on stage and histology grade among screen-eligible
patients. Patients with a high UPC score were more
likely to be screen-detected than those with a low
score or those with minimum PCP visits, 42, 37, and
31 %, respectively (P < 0.0001). Rural patients were more
likely to be symptom-detected than urban patients: 67 and
60 %, respectively (P < 0.001).
The variation in percent screen-detected cancers by
RHA for all patients and screen-eligible patients only is
shown in Fig. 2. Approximately 50 % of screen-eligible
women were screen-detected in four RHAs, 40 % in four
RHAs and only 10 % in one RHA.
Figure 3 shows the forest plot of the adjusted odds ra-
tios from the multivariable logistic regression model in
which the outcome is screen-detected cancer. RHAs that
had similar estimated odds were grouped together. Pa-
tients outside of the screening-eligible age group were
less likely to be screen-detected except for age group
70–74 (OR: 0.93, 95 % CI: 0.80–1.06). The likelihood
of being screen-detected increased with decreasing
disease stage. Compared to stage I cancer, the esti-
mated odds ratio of being screen-detected was 1.57,
0.37, 0.19 and 0.12 for in situ, stages II, III, and IV
cancers, respectively (P < 0.001). Having a comorbidity
index greater than or equal to 2 was associated with
a decreased odds of being screen-detected comparing
to those with a comorbidity index less than 2 (OR:
0.73, 95 % CI: 0.65–0.88).
Figure 4 shows significant interaction between RHA
and time period. The probability of screen-detected
cancer increased in all regions from 2004–2006 to
2007–2010, however, it increased to a greater extent in
RHAs 2 and 8 than other RHAs (P < 0.001).
Diagnostic interval
Table 2 shows the unadjusted time to diagnosis by detec-
tion method. Three hundred forty six symptom-detected
patients (4.5 % of symptom-detected patients) were ex-
cluded from the analysis because they did not have a
visit with a PCP within 6 months prior to their first diag-
nostic test. The median (90th percentile) time to diagno-
sis was 19 (70) and 21 (92) days for screen- and
symptom-detected breast cancers, respectively. Cancer
stage was inversely related to the diagnostic interval in
symptom-detected women: as cancer stage increased
from in situ to stage IV, the median diagnostic interval
decreased from 49 to 13 days. The relationship was
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Table 1 Relationship between demographic, clinical, and healthcare factors and breast cancer detection mode
Factor Total Screen detected Symptom detected
N (12373) N (4747) %a (38.4) N (7626) %a (61.6)
Demographic factors
Age*
39- 661 0 (0) 661 (100)
40–49 2660 838 (31.5) 1822 (68.5)
50–69 6046 2857 (47.3) 3189 (52.7)
70–74 1056 487 (46.1) 569 (53.9)
75+ 1950 565 (29.0) 1385 (71.0)
Neighborhood Income Quintile*
> 80 % 2694 1121 (41.6) 1573 (58.4)
60 % ~ 80 % 2388 922 (38.6) 1466 (61.4)
40–60 % 2547 967 (38.0) 1580 (62.0)
20 % ~ 40 % 2443 911 (37.3) 1532 (62.7)
< 20 % 2247 809 (36.0) 1438 (64.0)
Missing 54 17 (31.5) 37 (68.5)
Clinical factors
Stage*
In Situ 1588 967 (60.9) 621 (39.1)
I 4803 2440 (50.8) 2363 (49.2)
II 3821 1017 (26.6) 2804 (73.4)
III 1489 230 (15.4) 1259 (84.6)
IV 405 43 (10.6) 362 (89.4)
Missing 267 50 (18.7) 217 (81.3)
Histological Grade*
Well differentiated 2359 1165 (49.4) 1194 (50.6)
Moderately differentiated 4976 1977 (39.7) 2999 (60.3)
Poorly or undifferentiated 4408 1331 (30.2) 3077 (69.8)
Unknown/Not stated/Not applicable 630 274 (43.5) 356 (56.5)
Charlson Comorbidity Index*
0 8961 3507 (39.1) 5454 (60.9)
1 2348 912 (38.8) 1436 (61.2)
> =2 1064 328 (30.8) 736 (69.2)
Healthcare factors
Time Period*
2004–2006 5004 1732 (34.6) 3272 (65.4)
2007–2010 7369 3015 (40.9) 4354 (59.1)
Usual Provider Continuity*
High continuity (>0.75) 5037 2104 (41.8) 2933 (58.2)
Low continuity (<=0.75) 5731 2139 (37.3) 3592 (62.7)
Minimum doctor visits 1605 504 (31.4) 1101 (68.6)
Community Size and Metropolitan Influence Zone*
Urban 9741 3872 (39.7) 5869 (60.3)
Rural 2632 875 (33.2) 1757 (66.8)
aPercentages are row percents. *P-value < 0.001
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much attenuated in the screen-detected group, however;
in situ cancers had a median time of 30 days while all in-
vasive cancers (stage I through IV) had a median of
about 16 days. There was also significant variation in
time to diagnosis by health region: the median diagnos-
tic interval ranged from 7 to 42 days in the screen-
detected group and from 13 to 33 days in the symptom-
detected group.
Table 3 shows the results of the quantile regression
models for the median and the 90 % quantile for the two
detection methods, based on a simplified model that did
not include any interaction term.
RHA and cancer stage had the strongest associations
with the time to diagnosis for both screen- and
symptom-detected cancers, though the associations
differed by detection mode. The estimated median
time to diagnosis ranged from 4 to 37 days depending
on the RHA in the screen-detected cancers (P < 0.005)
and from 17 to 33 days in the symptom-detected can-
cers (P < 0.005), holding other factors at the reference
levels. The dissimilar patterns of the adjusted median
and 90th percentile diagnostic intervals depicted in
Fig. 5 illustrate the extent of regional variation. A
longer median (90th percentile) in a given RHA for a
given detection mode does not necessarily translate
into a longer median (90th percentile) for the other
detection mode in the same RHA.
Similarly, cancer stage showed a different pattern of
variation in the screen- and symptom-detected groups.
In symptom-detected cancers, the estimated median
time to diagnosis decreased monotonically with increas-
ing stage (45, 20, 14, 13 and 8 days for in situ, stage I, II,
II, and IV, respectively, P < 0.005); the estimated median
time in screen-detected cancers also decreased with in-
creasing stage but had a much smaller range (15, 4, 4, 4
and 1 days for in situ, stage I, II, II, and IV, respectively,
P < 0.005), holding other factors at the reference levels.
For symptom-detected patients, the effect of RHA
on the length of the diagnostic interval was modified
by the time period.1 Figure 6 illustrates the effect
modification of time period on RHA observed in the
median time to diagnosis. From 2004–2006 to 2007–
2010, the median diagnostic interval increased dra-
matically by 18 days in RHA 2 (P < 0.001), increased
by 3 days in RHAs 1, 3 and 8 (P < 0.001), decreased
by about 6 days in RHA 4 (P < 0.001), and remained
largely the same in RHAs 5, 6, 7, and 9. Overall, the
median diagnostic intervals were less than a month
for all RHAs except RHA 2 in 2007–2010, where the
median diagnostic interval was 41 days.
Fig. 2 Percent of screen-detected breast cancer by health region (RHA). The black histograms represent the percent in the entire patient cohort
and the grey histograms represent the percent in the screen-eligible patients, i.e. those aged 50 to 69 years. RHAs are ordered according to the
percent screen-detection from high to low in the entire patient population
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Discussion
In Alberta Canada, a province with a free, long-standing,
organized screening program, about 38 % of cancers
were screen-detected; among the age-eligible population
it was 47 %. In our study, those aged 70–74 were as
likely as those aged 50–69 to have screen-detected
cancer. The median time to diagnosis was similar for
screen- and symptom-detected breast cancers at 19 and
21 days, respectively. At the 90th percentile, however, the
time to diagnosis was 70 days in screen-detected breast
cancers compared to 92 days in symptom-detected
breast cancers. Region of residence and cancer stage had
the strongest associations with both detection mode and
time to diagnosis.
The percent of screen-detected cancers varied from
about 10 to 50 % by RHA, however, one RHA was re-
sponsible for most of the variation as eight of the nine
RHAs ranged from 40–50 % of age-eligible women being
screen-detected. The RHA with only 10 % screen-
detected breast cancers is a geographically large rural/re-
mote region in the northern-most part of the province;
approximately 20 % of the population is Aboriginal [24].
Some of the remote communities only have access to
screening mammography through a mobile unit via an
ice road during winter months. Other studies have re-
ported similar challenges in the screening of breast can-
cer among vulnerable populations in such remote
regions [25]. The screening program has now developed
a special program to encourage screening (for all
screeenable cancers) in this region.
As expected, screen-detected cancers were much
more likely to be early stage tumours (in situ or
stage I) than symptom-detected cancers. In situ can-
cers accounted for 20 % of screen-detected cancers
and 8 % of symptomatic cancers, similar to findings
in other jurisdictions [26]. Compared to symptom-
Fig. 4 An illustration of the effect modification on percent
screening-detection. The percent screening detected female breast
cancers in different RHAs was modified by the time period in
women diagnosed in Alberta, Canada in years 2004–2010
Fig. 3 The adjusted odds ratio of screen-detected female breast cancer diagnosed in Alberta, Canada (2004–2010).1 Adjusted for all the variables
shown plus the interaction terms of RHA by Time Period; 2The reference group is: age group 50–69, cancer stage 1, usual provider
continuity > 0.75, Charlson comorbidity index 0 or 1, RHA 3/6, and time period 2004–2006.*RHAs that have similar estimated odds were
grouped together. The reference RHAs are the metropolitan regions, 3&6
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Table 2 Median and 90th percentile in days of the diagnostic interval by detection mode
Factor Screen-detected (n = 4747) Symptom-detected (n = 7280)
Median 90 % P-value Median 90 % P-value
Overall 19 70 21 92
Demographic factors
Age
39- NA NA 0.10 21 80 <0.001
40–49 21 91 21 98
50–69 19 69 21 100
70–74 19 66 23 106
75+ 18 60 20 70
Neighborhood Income Quintile
> 80 % 17 77 0.046 21 102 0.49
60 % ~ 80 % 20 70 21 93
40–60 % 19 66 21 98
20 % ~ 40 % 19 70 22 88
< 20 % 22 68 21 83
Missing 37 130 26.5 75
CLINICAL FACTORS
Stage
In Situ 30 87 <0.001 49 156 <0.001
I 15 57.5 25 106
II 16 71 19 66
III 15 123.5 17 71
IV 16 83 13 65
Missing 38 133.5 19.5 97
Histological Grade
Well differentiated 17 62 0.008 28 112 <0.001
Moderately differentiated 18 68 21 93
Poorly or undifferentiated 20 73 19 74
Unknown/ Not stated/ Not applicable 34 100 35 135.5
Charlson Comorbidity Index
0 19 70 0.067 21 98 0.004
1 21 75 20 81
≥ 2 19 63 20 86
Healthcare factors
Regional Health Authority
1 29.5 83.5 <0.001 26 106 <0.001
2 41.5 110 33 128
3 25 73 25 98
4 29 70 22 84
5 19 62 19 100
6 7 54 17 87
7 19 69 16 69
8 29.5 181 13 86
9 29.5 57.5 14 58
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detected cancers, screen-detected cancers also tended
to have a lower histological grade. Although early
detection through screening has long-term survival
advantage [4–6, 27], it also results in “over” detec-
tion leading to over treatment in a proportion of
women [26, 28]. From the current study we are not
able to assess this fraction. More research is needed
to assess optimal histopathologic diagnosis [29] and
treatment for in situ cancers to minimize patient
harm and resource waste caused by over treatment.
Cancer patients with a co-morbidity index two or
above and those with a low UPC index were less
likely to be detected by screening. These findings are
consistent with the literature, suggesting that dealing
with chronic diseases may divert patients’ and health
care providers’ attention from preventive cancer care
services [30]. Further, if women have other diseases
that are likely to be fatal within a few years, screening
may not be appropriate. Patients ‘attached’ to a pri-
mary care physician are more likely to receive pre-
ventive care [31–33].
The patterns of variation in time to diagnosis
differed by RHA and stage for each mode of diagno-
sis. We hypothesize that the rural regions that had
the most extreme diagnostic intervals or diagnostic
interval increases over time may suffer from lack of
specific resources, such as radiologists or patholo-
gists, as shortage of physician and other healthcare
resources is associated with diagnostic delay [33–35].
Time to diagnosis also differed between the two
metropolitan areas (RHA 3 and 6) with a larger dif-
ference in screen-detected cancers. This is likely ex-
plained by a program in RHA 6 that specifies the
radiologist’s role in arranging follow-up tests on the
same day for abnormal mammogram results. It is
hypothesized that communication and referral prob-
lems could be responsible for variations in diagnostic
intervals in urban and rural centers [36–38]. Closer
inspection of communication, referral patterns and
healthcare resources is needed to identify ways to
minimize regional variation in timeliness of diagnos-
tic care.
Higher stage cancers that were symptom-detected
were diagnosed more quickly than those with a lower
stage. This is consistent with other studies that have
found shorter diagnostic intervals for the most symp-
tomatic cases [39, 40]. Upon further inspection we found
that most of the variation in time to diagnosis of
symptom-detected cancers by cancer stage was due to a
longer time from the PCP visit to the first test for low
stage cancers than high stage cancers (data not shown),
consistent with clinical practice to prioritize diagnostic
tests based on patient symptoms. Interestingly, the in-
verse relationship between time and cancer stage was
much less evident for screen-detected cancers, as inva-
sive cancers of all stages had a median diagnostic inter-
val of approximately 16 days. We hypothesize that the
procedures and communication between providers fol-
lowing screen-detection of breast abnormalities are
more established and coordinated compared to that for
symptom-detected breast abnormalities, and since mam-
mography does not clearly differentiate stage, all are
treated alike until biopsy results are available. Clear pro-
vider communication of test results, and physician docu-
mentation of the follow-up plan have been identified as
important factors that facilitate patient receipt of follow-
up care [36, 11, 41].
We found that 47 % of screen-eligible women by
age were screen-detected, which is a little lower than
the 55 % reported in West Midlands, UK [42]. In
2009–10, the overall screening rate in Alberta was
about 57.3 % which is lower than the target 70 %
that the Canadian programs set in 2006 [43] but
higher than the Canadian average of about 52 %
[44]. Although screening uptake is not optimal, there
is a clear and significant stage shift towards earlier
stage in the screen-detected cancers compared to the
symptom-detected ones observed in the current study, sug-
gesting that the screening program in Alberta is effective.
The large regional variation in both percent screen-
Table 2 Median and 90th percentile in days of the diagnostic interval by detection mode (Continued)
Time Period
2004–2006 18 67 0.024 21 87 0.72
2007–2010 20 73 21 97
Usual Provider Continuity
High continuity (>0.75) 19 67 0.48 22 91 <0.001
Low continuity (<=0.75) 20 74 22 99
Minimum doctor visits 18 70 18 63
Community Size and Metropolitan Influence Zone
Urban 17 69 <0.001 21 93 0.01
Rural 26 72 20 88
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Table 3 Quantile regression estimates of the median and 90th percentile of diagnostic interval by detection mode. The estimate
associated with each category is the difference in days when compared to the reference variable category
Factor Screen-detected (n = 4747) Symptom-detected (n = 7280)
Quantile 50 % Quantile 90 % Quantile 50 % Quantile 90 %
Days P-value Days P-value Days P-value Days P-value
Intercept




39- NA NA NA NA −1.0 0.29 −9.7 0.05
40–49 0 1.00 14 * −0.8 0.19 1.6 0.72
70–74 0 1.00 4.9 0.26 1.2 0.42 −1.2 0.88
75+ 1.0 0.19 −4.9 0.19 −1.4 0.07 −19.7 **
Neighborhood income quintile
> 80 % (Ref.)
60 % ~ 80 % 0 1.00 −3.3 0.52 1.6 0.06 −7.4 0.16
40–60 % 1.0 0.17 −6.9 0.15 0.6 0.44 −3.9 0.48
20 % ~ 40 % 2.0 ** −2.9 0.54 1.8 * −7.4 0.20
< 20 % 2.0 ** −8.4 0.11 1.4 0.11 −9.4 0.10




In Situ 11.0 ** 28.0 ** 24.8 ** 49.2 **
II 0.0 1.00 9.3 * −6.4 ** −36.7 **
III 0.0 1.00 60.8 ** −7.0 ** −29.8 **
IV −3.0 0.27 16.0 0.42 −12.2 ** −37.7 **
Missing 16.0 ** 37.4 0.16 −5.6 * −1.5 0.87
Charlson comorbidity index
0/1 (Ref.)




1 20.0 ** 37.5 ** 7.8 ** 16.3 0.07
2 30.0 ** 50.2 ** 12.6 ** 30.5 **
3 16.0 ** 18.9 ** 7.4 ** 5.7 0.20
4 19.0 ** 19.3 * 6.0 ** −2.5 0.71
5 10.0 ** 21.4 0.12 2.8 0.17 4.7 0.70
7 6.0 * 9.6 0.22 1.2 0.47 −21.5 *
8 22.0 ** 118.8 ** −3.4 0.06 −9.3 0.54
9 21.0 * 6.4 0.97 −3.0 0.27 −17.7 *
Time Period
2004–2006 (Ref.)
2007–2010 1.0 * 5.9 0.06 0.2 0.70 6.1 0.06
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detected and time to diagnosis, however, suggests there is
significant room for improvement.
The major strength of the study is that we studied a
population-based incident case cohort that included all
women with a first-ever breast cancer diagnosis over a
6-year period. Thus, survivor bias is minimal in our
study. It also allows for the assessment of changes over
time. The major limitations of this study are: 1) lack of
patient level information that may have explained some
of the variation in percent screen-detected cancer based
on patient choice due to education, screening awareness
and different values placed on screening; 2) lack of
detailed clinical information that could affect time to
diagnosis, such as breast density, which may explain the
shorter diagnostic interval at 90th percentile for older
patients; and 3) lack of registry data on molecular bio-
markers, e.g. ER, PR and triple negative, which is im-
portant to understand the implications of delay in
diagnosis for the more aggressive phenotypes. Addition-
ally, issues related to access to healthcare services such
as access to a PCP, screening mammography, biopsy and
pathologist were not investigated due to the limitation of
the data sources, however, the RHA variable served as a
proxy for the access factors to some extent.
Fig. 5 Maps of Alberta displaying regional variation in diagnostic interval by detection mode. The model based median and 90th percentile
estimates of the diagnostic interval are for urban patients with stage I cancer, in age group 50–69, and diagnosed in years 2004–2006. The map
legends R1 – R9 represent RHA1 – RHA9. The two solid squares in R3 and R6 indicate the location of the two metropolitan areas
Table 3 Quantile regression estimates of the median and 90th percentile of diagnostic interval by detection mode. The estimate
associated with each category is the difference in days when compared to the reference variable category (Continued)
Usual Provider Continuity
High continuity (>0.75, Ref.)
Low continuity (<=0.75) −0.0 1.00 5.4 0.12 0.4 0.50 2.9 0.46
Minimum doctor visits −1.0 0.26 −2.77 0.62 −2.0 * −19.2 **
Community Size and Metropolitan Influence Zone
Urban (Ref.)
Rural 3.0 * −2.3 0.66 −1.2 0.20 1.7 0.75
**P-value < 0.005 *P-value < 0.05
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Conclusions
Population-based studies are important for assessing
healthcare efficiency and identifying disparities within
the typical clinical practice environment. The significant
variation in mode of detection and time to diagnosis
across RHAs found in the current study suggests there
are important differences in local coordination of breast
cancer diagnosis. Similar regional variation in healthcare
has been reported in several other jurisdictions, and for
other diseases, indicating a need for routine monitoring
within and/or across provinces (insurance providers)
[45–48]. The public reporting efforts that have begun in
the United Kingdom, Canada, and elsewhere [49–51] are
good starting points for identifying variation but local
insurers and/or healthcare providers must take it upon
themselves to properly identify and address root causes
to healthcare variation through programming and moni-
toring in order to properly address them.
Endnote
1In the analysis of effect modification, health regions
have been grouped according to their median diagnostic
interval estimates and their changes over time, in order
to make Fig. 6 less busy while keeping the important
findings intact.
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